✓ Every entry linked to its official government source

Clinical-trial readouts & FDA AdComm meetings — every entry source-anchored.

Upcoming clinical-trial readout windows (from ClinicalTrials.gov) and FDA Advisory Committee (AdComm) meetings (from the Federal Register), each linked to its official record and clearly labelled confirmed (a scheduled FDA meeting or completed event) or estimated (the sponsor's projected trial-completion date). Public scheduling data, not investment advice.

See the calendar → Get the feed / API

What "source-anchored" means here

Every row is read directly from an official government field and links straight back to it, stamped with the date we last checked. We do not dress up an estimate as a fixed date: trial-readout rows carry the sponsor's estimated primary-completion date (which can slip), while FDA AdComm meetings carry a confirmed, scheduled date from the Federal Register Notice of Meeting. Each row says which it is, and you can audit it in one click.

601

upcoming source-anchored catalysts

600

trial primary-completion / readout dates EST

75

FDA AdComm meetings CONFIRMED

257

mapped to a public ticker

Most upcoming entries are clinical-trial readout windows carrying the sponsor's estimated primary-completion date (it can slip). FDA AdComm meetings carry a confirmed scheduled date. Every row is labelled and linked to its official source.

Soonest upcoming catalysts

Source-checked 2026-11-04 · refreshed daily · full calendar →

Date	Event	Company	Drug	Official source & verification
2026-11-05 in 1d ESTIMATED	READOUT Pediatric Long-Term Follow-up and Rollover Study Phase 4 · Diffuse Astrocytoma, Anaplastic Astrocytoma	NVS NOVARTIS AG	dabrafenib, trametinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-05 in 1d ESTIMATED	READOUT Rollover Study to Provide Continued Treatment for Participants With B-Cell Malig Phase 2 · B-Cell Malignancies	INCY INCYTE CORP	Parsaclisib, parsaclisib + itacitinib, p	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-05 in 1d ESTIMATED	READOUT A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metast Phase 1/2 · Prostate Cancer	AZN ASTRAZENECA PLC	AZD9750, AZD5305	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-09 in 5d ESTIMATED	READOUT A Platform Study of Novel Immunotherapy Combinations in Participants With Previo Phase 2 · Lung Cancer, Non-Small Cell	GlaxoSmithKline	Pembrolizumab, Dostarlimab, Belrestotug,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-11 in 7d ESTIMATED	READOUT PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metast Phase 2 · Cervical Cancer, HPV-Related Carcinoma	PGEN PRECIGEN, INC.	PRGN-2009 plus Pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-12 in 8d ESTIMATED	READOUT A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In Peop Phase 2 · Atopic Dermatitis	PFE PFIZER INC	PF-07275315, PF-07264660	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-13 in 9d ESTIMATED	READOUT A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination Wi Phase 1/2 · Advanced Solid Tumors	REGN REGENERON PHARMACEUTICALS, I	REGN7075, Cemiplimab, Platinum-based dou	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-13 in 9d ESTIMATED	READOUT A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compar Phase 3 · Breast Cancer	Hoffmann-La Roche	Inavolisib, Fulvestrant, Alpelisib, Bupr	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-13 in 9d ESTIMATED	READOUT Study of Olatorepatide in Adult Participants Living With Overweight or Obesity i Phase 2 · Overweight or Obesity	REGN REGENERON PHARMACEUTICALS, I	Olatorepatide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-14 in 10d ESTIMATED	READOUT A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Di Phase 3 · Type 2 Diabetes Mellitus (T2DM)	BrightGene Bio-Medical Technology	Drug: 5 mg BGM0504 Administered SC, Drug	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-14 in 10d ESTIMATED	READOUT A Study of BGM0504 in Participants With Type 2 Diabetes Phase 3 · Type 2 Diabetes Mellitus (T2DM)	BrightGene Bio-Medical Technology	Drug: 5 mg BGM0504 Administered SC, Drug	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-15 in 11d ESTIMATED	READOUT Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions. Phase 4 · Sciatica Acute, Lumbar Spinal Stenosis	Primus Pharmaceuticals	Metaxalone 640 mg Oral Tablet	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-15 in 11d ESTIMATED	READOUT Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Gla Phase 2 · Glaucoma, Open-Angle, Ocular Hypertension	PolyActiva Pty Ltd	PA5108 Ocular Implant low dose, PA5108 O	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-16 in 12d ESTIMATED	READOUT A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Gener Phase 2/3 · Generalized Myasthenia Gravis	UCB Biopharma SRL	Zilucoplan	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-17 in 13d ESTIMATED	READOUT AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 Phase 2 · Gastric Cancer, Gastroesophageal Junction Cancer	AZN ASTRAZENECA PLC	AZD0901, 5-Fluorouracil, Leucovorin, l-l	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-17 in 13d ESTIMATED	READOUT A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemo Phase 4 · Haemophilia A (Moderate or Severe), Hemophilia, Classic	Swedish Orphan Biovitrum	Efanesoctocog alfa	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-18 in 14d ESTIMATED	READOUT Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polym Phase 2/3 · Small Cell Lung Cancer	Han Xu, M.D., Ph.D., FAPCR, Medica	ETOPOSIDE - Usual, ETOPOSIDE - Study	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-18 in 14d ESTIMATED	READOUT Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucl Phase 2/3 · Prostate Cancer	Han Xu, M.D., Ph.D., FAPCR, Sponso	Abiraterone - Usual, Abiraterone - Study	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-18 in 14d ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Ac Phase 3 · Sjögren's Syndrome	BMY BRISTOL MYERS SQUIBB CO	Deucravacitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-18 in 14d ESTIMATED	READOUT Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymo Phase 2/3 · ALK-Positive Non-Small Cell Lung Cancer (NSCLC)	Medicine Invention Design, Inc	ALECENSA - alectinib hydrochloride capsu	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-18 in 14d ESTIMATED	READOUT A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular D Phase 2 · Duchenne Muscular Dystrophy	Hoffmann-La Roche	Satralizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-18 in 14d ESTIMATED	READOUT An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer Phase 2 · Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)	ToLymph Inc.	SMS001	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-19 in 15d ESTIMATED	READOUT A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Par Phase 4 · Severe Hemophilia A, Moderate Hemophilia A	Hoffmann-La Roche	Emicizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-19 in 15d ESTIMATED	READOUT A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participant Phase 2 · Alzheimer's Disease	Hoffmann-La Roche	RO7269162	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change
2026-11-19 in 15d ESTIMATED	READOUT A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatiti Phase 2 · Dermatitis, Atopic	Janssen Research & Development, LL	JNJ-95597528	ClinicalTrials.gov ↗ ✓ Source-checked 2026-11-04 Sponsor-projected date — can change